Harnessing Functional Genomics to Reverse Chemoresistance in Breast Cancer
作者： Brian Bodemann
DOI: 10.21236/ADA484470
关键词: Trastuzumab 、 Targeted therapy 、 Breast cancer 、 Functional genomics 、 Biology 、 Human genome 、 Breast cancer cell line 、 Monoclonal antibody 、 Cancer research 、 Antibody 、 Bioinformatics
摘要: Abstract : Targeted therapy has proven to be an effective strategy in the treatment of breast cancer. An example successful targeted is trastuzumab, a humanized monoclonal antibody that binds extracellular domain HER2, receptor which overexpressed many cancers. The goal my project identify molecular targets for conjunctive will increase efficacy trastuzumab therapy. To necessary cancer cell survival presence line with known cytostatic sensitivity screened using high throughput assay unique small interfering (si)RNA library targeting all 21,125 genes human genome database. This information help new synergistic combinations existing drugs and novel therapeutic can act synergistically as initial upon development resistance. During time covered by this annual summary, I have made major progress towards fulfilling training requirements finished optimizing conditions execution screen outlined AIM1.
sci-hub.st 参考文章(71)
J. Downward, Prelude to an Anniversary for the RAS Oncogene Science. ,vol. 314, pp. 433- 434 ,(2006) , 10.1126/SCIENCE.1134727
M Frech, I Schlichting, A Wittinghofer, P Chardin, Guanine nucleotide binding properties of the mammalian RalA protein produced in Escherichia coli. Journal of Biological Chemistry. ,vol. 265, pp. 6353- 6359 ,(1990) , 10.1016/S0021-9258(19)39333-0
R. Emkey, S. Freedman, L.A. Feig, Characterization of a GTPase-activating protein for the Ras-related Ral protein. Journal of Biological Chemistry. ,vol. 266, pp. 9703- 9706 ,(1991) , 10.1016/S0021-9258(18)92877-2
J.H. Camonis, G. Mirey, Y. Mahe, C. Leprince, B. Meunier-Bisceuil, A. Sorkin, V. Jullien-Flores, RLIP76, an effector of the GTPase Ral, interacts with the AP2 complex: involvement of the Ral pathway in receptor endocytosis Journal of Cell Science. ,vol. 113, pp. 2837- 2844 ,(2000)
S. M. McWhirter, K. A. Fitzgerald, J. Rosains, D. C. Rowe, D. T. Golenbock, T. Maniatis, IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts Proceedings of the National Academy of Sciences of the United States of America. ,vol. 101, pp. 233- 238 ,(2004) , 10.1073/PNAS.2237236100
Serge Moskalenko, Dale O. Henry, Carine Rosse, Gladys Mirey, Jacques H. Camonis, Michael A. White, The exocyst is a Ral effector complex Nature Cell Biology. ,vol. 4, pp. 66- 72 ,(2002) , 10.1038/NCB728
Yusheng Wu, Xibin Liao, Ruifang Wang, Xiao-Song Xie, Jef K. De Brabander, Total Synthesis and Initial Structure−Function Analysis of the Potent V-ATPase Inhibitors Salicylihalamide A and Related Compounds Journal of the American Chemical Society. ,vol. 124, pp. 3245- 3253 ,(2002) , 10.1021/JA0177713
Mary Ann Jordan, Leslie Wilson, Microtubules as a target for anticancer drugs. Nature Reviews Cancer. ,vol. 4, pp. 253- 265 ,(2004) , 10.1038/NRC1317
Yuchen Chien, Sungchan Kim, Ron Bumeister, Yueh-Ming Loo, Sung Won Kwon, Cynthia L Johnson, Mirey G Balakireva, Yves Romeo, Levy Kopelovich, Michael Gale, Charles Yeaman, Jacques H Camonis, Yingming Zhao, Michael A White, None, RalB GTPase-Mediated Activation of the IκB Family Kinase TBK1 Couples Innate Immune Signaling to Tumor Cell Survival Cell. ,vol. 127, pp. 157- 170 ,(2006) , 10.1016/J.CELL.2006.08.034
Jacques H. Camonis, Michael A. White, Ral GTPases: corrupting the exocyst in cancer cells Trends in Cell Biology. ,vol. 15, pp. 327- 332 ,(2005) , 10.1016/J.TCB.2005.04.002